These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 4083263

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
    Chiuten DF, Valdivieso M, Bedikian A, Bodey GP, Freireich EJ.
    Cancer Treat Rep; 1985 Jun; 69(6):611-3. PubMed ID: 4016768
    [Abstract] [Full Text] [Related]

  • 3. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG.
    Cancer Res; 1993 Oct 15; 53(20):4828-36. PubMed ID: 8402669
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B, Ucar A, Reddy R, Livingstone AS, Markoe A, Schwade J, Richman SP, Donofrio K.
    Cancer; 1994 Oct 01; 74(7):1869-73. PubMed ID: 8082092
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase I trial of combination therapy with PALA and 5-FU.
    Meshad MW, Ervin TJ, Kufe D, Johnson RK, Blum RH, Frei E.
    Cancer Treat Rep; 1981 Oct 01; 65(3-4):331-4. PubMed ID: 6263472
    [Abstract] [Full Text] [Related]

  • 10. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA, Diggs CH, Scoltock M, Wiernik PH.
    Cancer Treat Rep; 1980 Oct 01; 64(2-3):339-42. PubMed ID: 7407767
    [Abstract] [Full Text] [Related]

  • 11. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
    Nassim MA, Rouini MR, Cripps MC, Shirazi FH, Veerasinghan S, Molepo JM, Obrocea M, Redmond D, Bates S, Fry D, Stewart DJ, Goel R.
    Oncol Rep; 1998 Oct 01; 5(1):217-21. PubMed ID: 9458325
    [Abstract] [Full Text] [Related]

  • 12. Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma.
    Lynch G, Kemeny N, Chun H, Martin D, Young C.
    Cancer Treat Rep; 1985 Feb 01; 69(2):179-84. PubMed ID: 3971391
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
    O'Dwyer PJ, Hudes GR, Colofiore J, Walczak J, Hoffman J, LaCreta FP, Comis RL, Martin DS, Ozols RF.
    J Natl Cancer Inst; 1991 Sep 04; 83(17):1235-40. PubMed ID: 1714507
    [Abstract] [Full Text] [Related]

  • 14. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
    Weiss GR, Ervin TJ, Meshad MW, Schade D, Branfman AR, Bruni RJ, Chadwick M, Kufe DW.
    Cancer Chemother Pharmacol; 1982 Sep 04; 8(3):301-4. PubMed ID: 7127661
    [Abstract] [Full Text] [Related]

  • 15. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
    Mann GB, Hortobagyi GN, Buzdar AU, Yap HY, Valdivieso M.
    Cancer; 1985 Sep 15; 56(6):1320-4. PubMed ID: 4027872
    [Abstract] [Full Text] [Related]

  • 16. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B, Sridhar KS, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Fodor M, Livingstone A.
    Cancer; 1991 Sep 15; 68(6):1242-6. PubMed ID: 1873776
    [Abstract] [Full Text] [Related]

  • 17. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C, Donehower RC, Speyer JL, Klecker R, Chabner BA.
    J Natl Cancer Inst; 1982 Feb 15; 68(2):227-31. PubMed ID: 6950156
    [Abstract] [Full Text] [Related]

  • 18. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
    Buroker TR, Moertel CG, Fleming TR, Everson LK, Cullinan SA, Krook JE, Mailliard JA, Marschke RF, Klaassen DJ, Laurie JA.
    J Clin Oncol; 1985 Dec 15; 3(12):1624-31. PubMed ID: 2933492
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
    O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL.
    J Clin Oncol; 1990 Sep 15; 8(9):1497-503. PubMed ID: 2391557
    [Abstract] [Full Text] [Related]

  • 20. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
    Grem JL, Yee LK, Schuler B, Hamilton JM, Chen AP, Chabuk C, Grollman F, Grabenc M, Allegra CJ, Takimoto CH.
    Ann Oncol; 2001 Nov 15; 12(11):1581-7. PubMed ID: 11822758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.